Share on StockTwits
 

Abbott Laboratories (NYSE:ABT) announced its earnings results on Wednesday. The company reported $0.58 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.58, AnalystRatings.Net reports. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.72 billion.

ABT has been the subject of a number of recent research reports. Analysts at Cowen and Company raised their price target on shares of Abbott Laboratories from $41.00 to $45.00 in a research note to investors on Friday, January 17th. On a related note, analysts at Morgan Stanley upgraded shares of Abbott Laboratories from an “equal weight” rating to an “overweight” rating in a research note to investors on Friday, January 17th. They now have a $45.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Abbott Laboratories from $48.00 to $49.00 in a research note to investors on Thursday, January 9th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. Abbott Laboratories presently has an average rating of “Hold” and a consensus price target of $39.64.

Shares of Abbott Laboratories (NYSE:ABT) opened at 39.12 on Wednesday. Abbott Laboratories has a 52-week low of $32.58 and a 52-week high of $39.86. The stock’s 50-day moving average is $38.16 and its 200-day moving average is $36.31. The company has a market cap of $60.487 billion and a price-to-earnings ratio of 20.60.

Abbott Laboratories (NYSE:ABT), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.